MENTICE AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.4 SEK | -0.82% |
|
-0.27% | -23.69% |
| Apr. 02 | Mentice Receives an Order of USD 795,000 for Development Services from A World-Leading Medtech Company | CI |
| Mar. 21 | Transcript : Mentice AB - Analyst/Investor Day |
| Sales 2023 | 274M 25.15M | Sales 2024 * | 335M 30.84M | Capitalization | 931M 85.56M |
|---|---|---|---|---|---|
| Net income 2023 | -2M -184K | Net income 2024 * | 20M 1.84M | EV / Sales 2023 | 4.28 x |
| Net cash position 2023 | 49.56M 4.56M | Net cash position 2024 * | 79.05M 7.27M | EV / Sales 2024 * | 2.54 x |
| P/E ratio 2023 |
-434
x | P/E ratio 2024 * |
46.7
x | Employees | 114 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 42.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on Mentice AB
More press releases
| 1 day | -0.82% | ||
| 1 week | -0.27% | ||
| Current month | +9.31% | ||
| 1 month | +13.75% | ||
| 3 months | -25.56% | ||
| 6 months | +31.41% | ||
| Current year | -23.69% |
1 week
35.50
38.60
1 month
32.0038.60
Current year
30.1071.40
1 year
25.1071.40
3 years
25.10185.00
5 years
25.10185.00
10 years
25.10185.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 59 | 98-12-31 | |
| Chief Executive Officer | 76 | 07-12-31 | |
Jonatan Sjostrom
COO | Chief Operating Officer | - | 23-09-13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 76 | 07-12-31 | |
Magnus Nilsson
CHM | Chairman | 68 | 22-04-26 |
| Director/Board Member | 71 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 36.4 | -0.82% | 9,682 |
| 24-04-24 | 36.7 | -3.93% | 3,848 |
| 24-04-23 | 38.2 | +7.61% | 7,961 |
| 24-04-22 | 35.5 | -1.39% | 2,099 |
| 24-04-19 | 36 | -1.37% | 5,559 |
Delayed Quote Nasdaq Stockholm, April 25, 2024 at 11:17 am EDT
More quotes
Mentice AB is a Sweden-based medical technology company. It provides software and hardware simulation solutions and related services for endovascular therapies. The Companyâs solutions help healthcare professionals acquire, retain, and enhance their procedural skills. The Companyâs solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. The Company also covers neurovascular, cardiovascular and peripheral interventions, among others. It is active globally.
Calendar
2024-05-03
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
36.4
SEK
Average target price
55.33
SEK
Spread / Average Target
+52.01%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -23.69% | 86.17M | |
| +72.64% | 12.34B | |
| -18.30% | 7.98B | |
| +15.38% | 7.19B | |
| +2.18% | 5.81B | |
| +6.51% | 5.04B | |
| +21.99% | 4.31B | |
| -22.71% | 4.03B | |
| -41.36% | 2.21B | |
| +0.87% | 1.99B |
- Stock Market
- Equities
- MNTC Stock
